Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.

IF 2 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2025-03-18 DOI:10.1177/03008916251327830

Jun Yang, Shen Zhang, Yu Yin, Zhi Li, Shitao Lu, Guanyin Ni, Xiaoli Zhu, Caifang Ni

{"title":"Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.","authors":"Jun Yang, Shen Zhang, Yu Yin, Zhi Li, Shitao Lu, Guanyin Ni, Xiaoli Zhu, Caifang Ni","doi":"10.1177/03008916251327830","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the safety and efficacy of hepatic arterial infusion chemotherapy followed by transarterial embolization (HAIC+TAE) to transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (uHCC).Materials and methods: The clinical data of patients who received HAIC+TAE or TACE between April 2020 and April 2022 was collected. Propensity score-matching was used to balance the baseline characteristics of the two groups. Tumor response according to mRECIST, median time to progression (TTP) and overall survival (OS) were investigated. ALBI score was applied to evaluate the changes of liver function and other relative adverse reactions were recorded.Results: A total of 98 patients with uHCC were enrolled in the study, including 71 in the TACE group and 27 in the HAIC+TAE group. After propensity score matching, 23 pairs of patients were investigated. The HAIC+TAE group showed a longer median TTP and OS than TACE group (mTTP 316 vs. 235 days, P=0.023; mOS 580 vs. 493 days, P=0.020). Objective response rates in HAIC+TAE group and TACE group were 65.2% and 47.8% (P=0.234). Disease-control rates were 87.0% and 82.6% (P=1.000). No significant difference was found in the incidence of adverse events between the two groups (P>0.05).Conclusion: The combination treatment strategy of HAIC+TAE in patients with uHCC appears to be a safe regimen, with the potential to prolong mTTP and mOS relative to TACE. The sequential application of this therapy merits consideration as an innovative treatment strategy for individuals with uHCC.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251327830"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916251327830","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare the safety and efficacy of hepatic arterial infusion chemotherapy followed by transarterial embolization (HAIC+TAE) to transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (uHCC).

Materials and methods: The clinical data of patients who received HAIC+TAE or TACE between April 2020 and April 2022 was collected. Propensity score-matching was used to balance the baseline characteristics of the two groups. Tumor response according to mRECIST, median time to progression (TTP) and overall survival (OS) were investigated. ALBI score was applied to evaluate the changes of liver function and other relative adverse reactions were recorded.

Results: A total of 98 patients with uHCC were enrolled in the study, including 71 in the TACE group and 27 in the HAIC+TAE group. After propensity score matching, 23 pairs of patients were investigated. The HAIC+TAE group showed a longer median TTP and OS than TACE group (mTTP 316 vs. 235 days, P=0.023; mOS 580 vs. 493 days, P=0.020). Objective response rates in HAIC+TAE group and TACE group were 65.2% and 47.8% (P=0.234). Disease-control rates were 87.0% and 82.6% (P=1.000). No significant difference was found in the incidence of adverse events between the two groups (P>0.05).

Conclusion: The combination treatment strategy of HAIC+TAE in patients with uHCC appears to be a safe regimen, with the potential to prolong mTTP and mOS relative to TACE. The sequential application of this therapy merits consideration as an innovative treatment strategy for individuals with uHCC.

查看原文本刊更多论文

肝动脉灌注化疗后经动脉栓塞治疗肝癌的疗效和安全性。

目的：比较肝动脉灌注化疗合并经动脉栓塞（HAIC+TAE）与经动脉化疗栓塞（TACE）治疗不可切除肝癌（uHCC）的安全性和有效性。材料与方法：收集2020年4月至2022年4月期间接受HAIC+TAE或TACE治疗的患者的临床资料。倾向评分匹配用于平衡两组的基线特征。根据mRECIST研究肿瘤反应，中位进展时间（TTP）和总生存期（OS）。采用ALBI评分评价肝功能变化，并记录其他相关不良反应。结果：共有98例uHCC患者入组，其中TACE组71例，HAIC+TAE组27例。倾向评分匹配后，对23对患者进行调查。HAIC+TAE组的中位TTP和OS均长于TACE组(mTTP为316天比235天，P=0.023；寿命580天和493天，P=0.020)。HAIC+TAE组和TACE组客观有效率分别为65.2%和47.8% （P=0.234）。疾病控制率分别为87.0%和82.6% （P=1.000）。两组患者不良事件发生率比较差异无统计学意义（P < 0.05）。结论：HAIC+TAE联合治疗uHCC患者是一种安全的治疗方案，相对于TACE有可能延长mTTP和mOS。这种疗法的顺序应用值得考虑作为一种创新的治疗策略，为个体与uHCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.